AU2001236737A1 - Method of reducing aluminum levels in the central nervous system - Google Patents

Method of reducing aluminum levels in the central nervous system

Info

Publication number
AU2001236737A1
AU2001236737A1 AU2001236737A AU3673701A AU2001236737A1 AU 2001236737 A1 AU2001236737 A1 AU 2001236737A1 AU 2001236737 A AU2001236737 A AU 2001236737A AU 3673701 A AU3673701 A AU 3673701A AU 2001236737 A1 AU2001236737 A1 AU 2001236737A1
Authority
AU
Australia
Prior art keywords
nervous system
central nervous
reducing aluminum
aluminum levels
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236737A
Inventor
Brian M. Berg
Warren J. Croom Jr.
Ian L. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, University of California filed Critical North Carolina State University
Publication of AU2001236737A1 publication Critical patent/AU2001236737A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001236737A 2000-02-08 2001-02-07 Method of reducing aluminum levels in the central nervous system Abandoned AU2001236737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/499,980 US6734166B1 (en) 2000-02-08 2000-02-08 Method of reducing aluminum levels in the central nervous system
US09499980 2000-02-08
PCT/US2001/003952 WO2001058409A2 (en) 2000-02-08 2001-02-07 Method of reducing aluminum levels in the central nervous system

Publications (1)

Publication Number Publication Date
AU2001236737A1 true AU2001236737A1 (en) 2001-08-20

Family

ID=23987548

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236737A Abandoned AU2001236737A1 (en) 2000-02-08 2001-02-07 Method of reducing aluminum levels in the central nervous system

Country Status (3)

Country Link
US (1) US6734166B1 (en)
AU (1) AU2001236737A1 (en)
WO (1) WO2001058409A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1349563B1 (en) * 2000-12-14 2009-12-02 Amylin Pharmaceuticals, Inc. Peptide pyy[3-36] for treatment of metabolic disorders
DE60335639D1 (en) * 2002-06-14 2011-02-17 Amylin Pharmaceuticals Inc PREVENTION AND / OR TREATMENT OF COLITIS ULCEROSA WITH PYY OR PYYE3-36Ü
EP2277527A3 (en) * 2003-01-17 2011-08-31 Ipsen Pharma Peptide YY analogs
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
EP2335716A3 (en) * 2004-02-11 2011-10-19 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
NZ548978A (en) 2004-02-11 2009-10-30 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
WO2005114212A2 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy4 (npy4)
EP2360180A3 (en) 2004-12-13 2012-02-08 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
CN109890205A (en) 2016-08-28 2019-06-14 以色列农业和农村发展部农业研究组织(范卡尼中心) The method for controlling the fungal infection in plant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
JP3265577B2 (en) 1992-10-13 2002-03-11 デューク・ユニバーシティ Method for measuring type 4 isoform of apolipoprotein E
SK121895A3 (en) 1993-03-29 1996-10-02 Univ Cincinnati Analogues of peptide yy and uses thereof
US5663192A (en) * 1994-10-20 1997-09-02 Eli Lilly And Company Heterocyclic neuropeptide Y receptor antagonists
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US5916869A (en) 1997-06-13 1999-06-29 North Carolina State University Method of treating birds in ovo

Also Published As

Publication number Publication date
US6734166B1 (en) 2004-05-11
WO2001058409A2 (en) 2001-08-16
WO2001058409A3 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
AU2001245928A1 (en) Electrolyzer and method of using the same
AU2002306870A1 (en) Pdstudio design system and method
AU2002213126A1 (en) Method and system for improving vision
AU2001249171A1 (en) Electrolysis method and system
AU2001229616A1 (en) System and method for determining muscle dysfunction
AU2002322039A1 (en) Railing advertising-surface, system and method
AU2002307768A1 (en) System and method for phytomonitoring
AU2002356311A1 (en) Anchor for vehicle, vehicle and anchor in combination, and method of using the anchor
AU2002241679A1 (en) Distribution system and method
AU2001284718A1 (en) Inflatable structure system and method for using the same
AU2001263129A1 (en) System and method for orthokeratology
AU2002324654A1 (en) Tie-down system and method
AU2002213227A1 (en) Generalizer system and method
AU2001236737A1 (en) Method of reducing aluminum levels in the central nervous system
AU2001287438A1 (en) System and method for allocating power
AU2001279850A1 (en) Method and arrangement for studsystem
AU2001294548A1 (en) Mud system and method
AU2001287437A1 (en) System and method for allocating power
AU2002246957A1 (en) Smart-caching system and method
AU7046601A (en) Method for the combined representation of morphology and dynamics in split-imageand volume-image methods
AU2001276049A1 (en) Method of enabling the spacing of metal units
AU2001295689A1 (en) Compositions and methods for regulating the nervous system
AU2001272859A1 (en) Camera-tracking system and method
AU2002310420A1 (en) Progressive system and methods
AU2002225303A1 (en) Adjustable partition system and method